Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers, has announced its participation in the Leerink Partners Global Healthcare Conference in Miami, Florida.
The company's President and CEO, Dr. Lara S. Sullivan, will engage in a fireside chat scheduled for March 10, 2025, at 2:20 PM EST. Investors and interested parties can access both the live webcast and replay of the presentation through the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website at ir.pyxisoncology.com.
Pyxis Oncology (Nasdaq: PYXS), un'azienda in fase clinica focalizzata sullo sviluppo di terapie di nuova generazione per tumori difficili da trattare, ha annunciato la sua partecipazione alla Leerink Partners Global Healthcare Conference a Miami, Florida.
Il Presidente e CEO dell'azienda, Dr. Lara S. Sullivan, parteciperà a un incontro informale programmato per il 10 marzo 2025, alle 14:20 EST. Gli investitori e le parti interessate possono accedere sia alla diretta web che alla registrazione della presentazione attraverso la pagina Eventi e Presentazioni nella sezione Relazioni con gli Investitori del sito web di Pyxis Oncology all'indirizzo ir.pyxisoncology.com.
Pyxis Oncology (Nasdaq: PYXS), una empresa en etapa clínica centrada en el desarrollo de terapias de próxima generación para cánceres difíciles de tratar, ha anunciado su participación en la Leerink Partners Global Healthcare Conference en Miami, Florida.
La Presidenta y CEO de la empresa, la Dra. Lara S. Sullivan, participará en una charla informal programada para el 10 de marzo de 2025, a las 2:20 PM EST. Los inversores y partes interesadas pueden acceder tanto a la transmisión en vivo como a la repetición de la presentación a través de la página de Eventos y Presentaciones en la sección de Relaciones con Inversores del sitio web de Pyxis Oncology en ir.pyxisoncology.com.
Pyxis Oncology (Nasdaq: PYXS)는 치료하기 어려운 암을 위한 차세대 치료제를 개발하는 임상 단계의 회사로, 플로리다 마이애미에서 열리는 Leerink Partners Global Healthcare Conference에 참여한다고 발표했습니다.
회사의 사장 겸 CEO인 Dr. Lara S. Sullivan은 2025년 3월 10일 오후 2시 20분 EST에 예정된 대화에 참여할 예정입니다. 투자자 및 관심 있는 분들은 Pyxis Oncology 웹사이트의 투자자 관계 섹션에 있는 이벤트 및 프레젠테이션 페이지를 통해 생중계 및 프레젠테이션 재생을 모두 이용할 수 있습니다: ir.pyxisoncology.com.
Pyxis Oncology (Nasdaq: PYXS), une entreprise en phase clinique axée sur le développement de thérapies de nouvelle génération pour des cancers difficiles à traiter, a annoncé sa participation à la Leerink Partners Global Healthcare Conference à Miami, en Floride.
La Présidente et CEO de l'entreprise, Dr. Lara S. Sullivan, participera à une discussion informelle prévue pour le 10 mars 2025 à 14h20 EST. Les investisseurs et les parties intéressées peuvent accéder à la fois à la diffusion en direct et à la rediffusion de la présentation via la page Événements & Présentations dans la section Relations Investisseurs du site Web de Pyxis Oncology à l'adresse ir.pyxisoncology.com.
Pyxis Oncology (Nasdaq: PYXS), ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien der nächsten Generation für schwer zu behandelnde Krebserkrankungen konzentriert, hat seine Teilnahme an der Leerink Partners Global Healthcare Conference in Miami, Florida, bekannt gegeben.
Die Präsidentin und CEO des Unternehmens, Dr. Lara S. Sullivan, wird an einem geplanten Gespräch teilnehmen, das für den 10. März 2025 um 14:20 Uhr EST angesetzt ist. Investoren und Interessierte können sowohl auf die Live-Übertragung als auch auf die Wiederholung der Präsentation über die Seite Veranstaltungen & Präsentationen im Bereich Investor Relations auf der Website von Pyxis Oncology unter ir.pyxisoncology.com zugreifen.
- None.
- None.
BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, March 10, 2025 at 2:20 PM EST at the Leerink Partners Global Healthcare Conference in Miami, Florida.
A live webcast and replay of the fireside chat will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-201 is designed to directly kill cancer cells and to address factors in the microenvironment that enable the uncontrolled proliferation and immune evasion of malignant tumors.
To learn more, visit www.pyxisoncology.com or follow us on X (formerly known as Twitter) and LinkedIn.
Pyxis Oncology Contact
Pamela Connealy
CFO and COO
ir@pyxisoncology.com
FAQ
When is Pyxis Oncology (PYXS) presenting at the Leerink Partners Healthcare Conference 2025?
How can investors watch Pyxis Oncology's (PYXS) Leerink Conference presentation?
What type of company is Pyxis Oncology (PYXS)?
Who will represent Pyxis Oncology (PYXS) at the 2025 Leerink Partners Conference?
